Merck will obtain the exclusive global license for Chinese pharmaceutical company Hansu’s HS-10535, an experimental oral drug that targets the GLP-1 receptor. Read more
https://fortune.com/img-assets/wp-content/uploads/2024/12/GettyImages-1251953326-e1734582075964.jpg?resize=1200,600
Source link